These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 21329636)
1. Rapid deterioration of renal insufficiency after magnetic resonance imaging with gadolinium-based contrast agent. Fujisaki K; Ono-Fujisaki A; Kura-Nakamura N; Komune N; Hirakawa N; Tsuruya K; Komune S; Iida M Clin Nephrol; 2011 Mar; 75(3):251-4. PubMed ID: 21329636 [TBL] [Abstract][Full Text] [Related]
2. The use of gadolinium for arterial interventions. Sambol EB; Van der Meer JG; Graham A; Goldstein LJ; Karwowski JK; Dayal R; Derubertis B; Kent KC Ann Vasc Surg; 2011 Apr; 25(3):366-76. PubMed ID: 21288688 [TBL] [Abstract][Full Text] [Related]
3. Serum Neutrophil Gelatinase-Associated Lipocalin and Urinary Kidney Injury Molecule-1 as Potential Biomarkers of Subclinical Nephrotoxicity After Gadolinium-Based and Iodinated-Based Contrast Media Exposure in Pediatric Patients with Normal Kidney Function. Spasojević-Dimitrijeva B; Kotur-Stevuljević J; Đukić M; Paripović D; Miloševski-Lomić G; Spasojević-Kalimanovska V; Pavićević P; Mitrović J; Kostić M Med Sci Monit; 2017 Sep; 23():4299-4305. PubMed ID: 28874655 [TBL] [Abstract][Full Text] [Related]
4. Risk of acute kidney injury after exposure to gadolinium-based contrast in patients with renal impairment. Chien CC; Wang HY; Wang JJ; Kan WC; Chien TW; Lin CY; Su SB Ren Fail; 2011; 33(8):758-64. PubMed ID: 21777176 [TBL] [Abstract][Full Text] [Related]
5. Safety of gadolinium contrast angiography in patients with chronic renal insufficiency. Sam AD; Morasch MD; Collins J; Song G; Chen R; Pereles FS J Vasc Surg; 2003 Aug; 38(2):313-8. PubMed ID: 12891113 [TBL] [Abstract][Full Text] [Related]
7. Gadolinium-based contrast exposure, nephrogenic systemic fibrosis, and gadolinium detection in tissue. Wiginton CD; Kelly B; Oto A; Jesse M; Aristimuno P; Ernst R; Chaljub G AJR Am J Roentgenol; 2008 Apr; 190(4):1060-8. PubMed ID: 18356456 [TBL] [Abstract][Full Text] [Related]
8. C-reactive protein levels and clinical symptoms following gadolinium administration in hemodialysis patients. Schieren G; Tokmak F; Lefringhausen L; van Bracht M; Perings C; Willers R; Günsel A; Kemper F; Wiesmüller GA; Rump LC Am J Kidney Dis; 2008 Jun; 51(6):976-86. PubMed ID: 18501785 [TBL] [Abstract][Full Text] [Related]
9. Nephrogenic systemic fibrosis: is gadolinium the missing piece to the puzzle? Bennett LK; Garrett AL Cutis; 2008 May; 81(5):421-6. PubMed ID: 18543594 [TBL] [Abstract][Full Text] [Related]
10. [Nephrotoxicity of contrast media in magnetic resonance tomography (MRI)]. Heuck A; Reiser M Internist (Berl); 1997 Dec; 38(12):1234-5. PubMed ID: 9465330 [No Abstract] [Full Text] [Related]
11. Nephrogenic systemic fibrosis in Japan: advisability of keeping the administered dose as low as possible. Tsushima Y; Takahashi-Taketomi A; Endo K Radiology; 2008 Jun; 247(3):915-6. PubMed ID: 18487548 [No Abstract] [Full Text] [Related]
12. [Nephrogenic systemic fibrosis as an adverse drug reaction of gadolinium-based contrast media for magnetic resonance imaging]. Giersig C Radiologe; 2007 Sep; 47(9):794-9. PubMed ID: 17713753 [TBL] [Abstract][Full Text] [Related]
13. Iron-mobilizing properties of the gadolinium-DTPA complex: clinical and experimental observations. Vorobiov M; Basok A; Tovbin D; Shnaider A; Katchko L; Rogachev B Nephrol Dial Transplant; 2003 May; 18(5):884-7. PubMed ID: 12686659 [TBL] [Abstract][Full Text] [Related]
14. Gadolinium-containing magnetic resonance imaging contrast and nephrogenic systemic fibrosis: a case-control study. Kallen AJ; Jhung MA; Cheng S; Hess T; Turabelidze G; Abramova L; Arduino M; Guarner J; Pollack B; Saab G; Patel PR Am J Kidney Dis; 2008 Jun; 51(6):966-75. PubMed ID: 18501784 [TBL] [Abstract][Full Text] [Related]